Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer

Table 3

Comparison of immunological indicators of patients in the two studied groups.

	DC-CIK group n = 53	Control group n = 53	value
CD3^+ T cell (%)
Pretreatment	55.17 ± 3.73	56.39 ± 4.40	0.127
Post-treatment	60.61 ± 3.63	53.62 ± 3.84	0.001
CD4^+ T cell (%)
Pretreatment	33.13 ± 4.09	32.75 ± 4.03	0.631
Post-treatment	36.51 ± 4.47	29.88 ± 4.08	0.001
CD8^+ T cell (%)
Pretreatment	27.17 ± 5.14	28.21 ± 5.16	0.301
Post-treatment	26.34 ± 5.19	28.65 ± 5.14	0.023
CD4^+/CD8^+ ratio
Pretreatment	1.43 ± 0.12	1.44 ± 0.13	0.682
Post-treatment	1.56 ± 0.14	1.17 ± 0.13	0.001
NK cell (%)
Pretreatment	16.52 ± 3.98	17.39 ± 4.09	0.270
Post-treatment	20.19 ± 4.22	15.59 ± 4.49	0.001

Notes: DC-CIK: dendritic cell-cytokine-induced killer.